Establishing a Proteomics-Based Signature of AKR1C3-Related Genes for Predicting the Prognosis of Prostate Cancer

Aldo-keto reductase family 1 member C3 (AKR1C3) plays an important role in prostate cancer (PCa) progression, particularly in castration-resistant prostate cancer (CRPC). It is necessary to establish a genetic signature associated with AKR1C3 that can be used to predict the prognosis of PCa patients and provide important information for clinical treatment decisions. AKR1C3-related genes were identified via label-free quantitative proteomics of the AKR1C3-overexpressing LNCaP cell line. A risk model was constructed through the analysis of clinical data, PPI, and Cox-selected risk genes. Cox regression analysis, Kaplan–Meier (K–M) curves, and receiver operating characteristic (ROC) curves were used to verify the accuracy of the model, and two external datasets were used to verify the reliability of the results. Subsequently, the tumor microenvironment and drug sensitivity were explored. Moreover, the roles of AKR1C3 in the progression of PCa were verified in LNCaP cells. MTT, colony formation, and EdU assays were conducted to explore cell proliferation and drug sensitivity to enzalutamide. Migration and invasion abilities were measured using wound-healing and transwell assays, and qPCR was used to assess the expression levels of AR target genes and EMT genes. CDC20, SRSF3, UQCRH, INCENP, TIMM10, TIMM13, POLR2L, and NDUFAB1 were identified as AKR1C3-associated risk genes. These risk genes, established using the prognostic model, can effectively predict the recurrence status, immune microenvironment, and drug sensitivity of PCa. Tumor-infiltrating lymphocytes and several immune checkpoints that promote cancer progression were higher in high-risk groups. Furthermore, there was a close correlation between the sensitivity of PCa patients to bicalutamide and docetaxel and the expression levels of the eight risk genes. Moreover, through in vitro experiments, Western blotting confirmed that AKR1C3 enhanced SRSF3, CDC20, and INCENP expression. We found that PCa cells with a high expression of AKR1C3 have high proliferation ability and high migration ability and were insensitive to enzalutamide. AKR1C3-associated genes had a significant role in the process of PCa, immune responses, and drug sensitivity and offer the potential for a novel model for prognostic prediction in PCa.

[1]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[2]  Yandong Miao,et al.  Prognostic implications of ferroptosis-associated gene signature in colon adenocarcinoma , 2021, World journal of clinical cases.

[3]  S. Tavaré,et al.  Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma , 2021, Cancer cell.

[4]  C. Liang,et al.  Identification of a Costimulatory Molecule-Related Signature for Predicting Prognostic Risk in Prostate Cancer , 2021, Frontiers in Genetics.

[5]  H. Maecker,et al.  IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC) , 2021, Journal for ImmunoTherapy of Cancer.

[6]  Tiancheng Xie,et al.  Identification and Validation of a Prognostic Signature for Prostate Cancer Based on Ferroptosis-Related Genes , 2021, Frontiers in Oncology.

[7]  S. Sakaguchi,et al.  Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells , 2021, Proceedings of the National Academy of Sciences.

[8]  Da-peng Wei,et al.  CDC20 and PTTG1 are Important Biomarkers and Potential Therapeutic Targets for Metastatic Prostate Cancer , 2021, Advances in Therapy.

[9]  F. Jadidi-Niaragh,et al.  The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. , 2021, Life sciences.

[10]  S. Tsoka,et al.  Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action , 2021, European journal of immunology.

[11]  Qiaolin Xu,et al.  Inhibition of SRSF3 Alleviates Proliferation and Migration of Gastric Cancer Cells by Regulating the PI3K/AKT/mTOR Signalling Pathway. , 2021, Folia biologica.

[12]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[13]  Peifeng Li,et al.  Emerging Roles of SRSF3 as a Therapeutic Target for Cancer , 2020, Frontiers in Oncology.

[14]  Jin-jian Lu,et al.  Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. , 2020, Pharmacology & therapeutics.

[15]  Weimin Cai,et al.  SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer , 2020, Theranostics.

[16]  Xiao Zhi Qiu,et al.  AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer , 2019, Molecular Cancer Therapeutics.

[17]  O. Ogawa,et al.  Consecutive Prostate Cancer Specimens Revealed Increased Aldo–Keto Reductase Family 1 Member C3 Expression with Progression to Castration-Resistant Prostate Cancer , 2019, Journal of clinical medicine.

[18]  Hai Huang,et al.  Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cells , 2019, EBioMedicine.

[19]  H. Hsu,et al.  MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer , 2019, Molecular Cancer.

[20]  Z. Tomková,et al.  RHOA and mDia1 Promotes Apoptosis of Breast Cancer Cells Via a High Dose of Doxorubicin Treatment , 2019, Open life sciences.

[21]  M. Mohsenzadegan,et al.  A Review of Preclinical Experiments Toward Targeting M2 Macrophages in Prostate Cancer. , 2019, Current drug targets.

[22]  L. Scott Enzalutamide: A Review in Castration-Resistant Prostate Cancer , 2018, Drugs.

[23]  T. Yi,et al.  Series test of cluster and network analysis for lupus nephritis, before and after IFN‐K‐immunosuppressive therapy , 2018, Nephrology.

[24]  Shan Xu,et al.  AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. , 2018, Urologic oncology.

[25]  Zhongqi Cui,et al.  Combining multi‐dimensional data to identify a key signature (gene and miRNA) of cisplatin‐resistant gastric cancer , 2018, Journal of cellular biochemistry.

[26]  G. van der Pluijm,et al.  Protocols for Migration and Invasion Studies in Prostate Cancer. , 2018, Methods in molecular biology.

[27]  D. Choi,et al.  The mitochondrial hinge protein, UQCRH, is a novel prognostic factor for hepatocellular carcinoma , 2017, Cancer medicine.

[28]  Wen-Jye Lin,et al.  Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis , 2016, Oncotarget.

[29]  S. Zhang,et al.  Identification of ubiquinol cytochrome c reductase hinge (UQCRH) as a potential diagnostic biomarker for lung adenocarcinoma , 2016, Open Biology.

[30]  Yusuke Nakamura,et al.  PRMT1 promotes mitosis of cancer cells through arginine methylation of INCENP , 2015, Oncotarget.

[31]  Yezi Zhu,et al.  Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. , 2015, Cancer research.

[32]  J. Vandesompele,et al.  Early Targets of miR-34a in Neuroblastoma* , 2014, Molecular & Cellular Proteomics.

[33]  Yuantong Tian,et al.  AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression , 2014, Diagnostic Pathology.

[34]  J. Bono,et al.  Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. , 2014, European journal of cancer.

[35]  N. Cox,et al.  Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines , 2014, Genome Biology.

[36]  L. Walker Treg and CTLA-4: Two intertwining pathways to immune tolerance , 2013, Journal of autoimmunity.

[37]  J. Schalken,et al.  Aldo-keto Reductase Family 1 Member C3 (AKR1C3) Is a Biomarker and Therapeutic Target for Castration-Resistant Prostate Cancer , 2012, Molecular medicine.

[38]  Yan Ma,et al.  Prospective nested case–control study of feature genes related to leukemic evolution of myelodysplastic syndrome , 2012, Molecular Biology Reports.

[39]  K. Aozasa,et al.  Infiltration of tumour‐associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer , 2011, BJU international.

[40]  L. V. D. Heuvel,et al.  The human nuclear-encoded acyl carrier subunit (NDUFAB1) of the mitochondrial complex I in human pathology , 1999, Journal of Inherited Metabolic Disease.

[41]  D. Gerloff,et al.  Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumour cells , 2001, Chromosoma.